Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 13/20 | 0.47 |
| ▸ | MAOA | P21397 | 5/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | RCOR1 | Q9UKL0 | 4/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | LIPC | P11150 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13836606 | 0.81 | PSEN1 (0.43) | KDM1AMAOAMAOBPSEN1PSEN2 | |
| SCHEMBL2315950 | 0.81 | KDM1A (0.43) | KDM1AMAOAMAOBRCOR1HDAC6 | |
| SCHEMBL10032825 | 0.81 | KDM1A (0.38) | KDM1AMAOAMAOBRCOR1SIGMAR1 | |
| SCHEMBL13836191 | 0.79 | LIPC (0.37) | KDM1AMAOAMAOBLIPCLIPG | |
| SCHEMBL2317127 | 0.78 | PSEN1 (0.41) | MAOAPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13836164 | 0.78 | DPEP1 (0.38) | KDM1AMAOAMAOBPSEN1PSEN2 | |
| SCHEMBL13836451 | 0.77 | P2RY14 (0.46) | KDM1AMAOAMAOBRCOR1PSEN1 | |
| SCHEMBL13836267 | 0.77 | P2RY14 (0.46) | KDM1AMAOAMAOBRCOR1PSEN1 | |
| SCHEMBL2315528 | 0.77 | PSEN1 (0.40) | MAOAPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1709487 | 0.77 | PSEN1 (0.40) | MAOAPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528890-A1 | AMINOCYCLOHEXANES AND AMINOTETRAHYDROPYRANS AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS | Pfizer Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120295923-A1 | Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators | PFIZER INC. | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295923-A1 | Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators | BACE1, BACE2, PSEN1 | KDM1A 3181/4885MAOA 1171/4885MAOB 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.